<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03459729</url>
  </required_header>
  <id_info>
    <org_study_id>PRO36718</org_study_id>
    <nct_id>NCT03459729</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic (PK) Analysis of Antitumor B in Patients With Oral Cancer</brief_title>
  <official_title>PK Analysis of Antitumor B in Patients With Oral Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical College of Wisconsin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical College of Wisconsin</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Window of Opportunity Clinical Trial. This study design permits examination of effects of&#xD;
      an oral agent on cancer patients during the &quot;window&quot; between diagnosis of their cancer and&#xD;
      their definitive cancer surgery. Similar to a phase 0 study, the trial design permits&#xD;
      examination of the biologic effects of an agent; in this study pharmacokinetic properties&#xD;
      will be examined.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Intervention Description:&#xD;
&#xD;
      Study participants will take the natural botanical compound ATB during a short window (7 to&#xD;
      28 days). Participants will provide blood samples, and saliva samples during Anti-tumor B&#xD;
      (ATB) administration and a portion of the initial tumor biopsy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 24, 2021</start_date>
  <completion_date type="Anticipated">December 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the Curve (AUC) for Saliva</measure>
    <time_frame>30, 60, 120, 180, 240, 360, 480, and 1,440 min on Day 1</time_frame>
    <description>The AUC will be calculated using software. The calculation will be mg/ml X hour.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the Curve for Plasma</measure>
    <time_frame>30, 60, 120, 180, 240, 360, 480, and 1,440 min on Day 1</time_frame>
    <description>The AUC will be calculated using software. The calculation will be mg/ml X hour.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax for Saliva</measure>
    <time_frame>Day 1</time_frame>
    <description>The Cmax will be calculated using software. The calculation will be ng/ml.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax for Plasma</measure>
    <time_frame>Day 1</time_frame>
    <description>The Cmax will be calculated using software. The calculation will be ng/ml.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">8</enrollment>
  <condition>Squamous Cell Carcinoma of the Oral Cavity</condition>
  <arm_group>
    <arm_group_label>Antitumor B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ATB will be administered on an outpatient basis.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antitumor B</intervention_name>
    <description>Study participants will take the natural botanical compound ATB during a short window (seven to 28 days). It will be administered at a dose of 1200 mg three times per day (roughly spaced every 8 hours).</description>
    <arm_group_label>Antitumor B</arm_group_label>
    <other_name>Zeng Sheng Ping</other_name>
    <other_name>ATB</other_name>
    <other_name>ACAPHA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Clinical diagnosis of oral cavity squamous cell cancer.&#xD;
&#xD;
          -  Patient can start study agent administration but histological confirmation of squamous&#xD;
             cell cancer (SCC) of the oral cavity (or histologic variants of SCC) by the&#xD;
             pathologist must happen within 7 days of registration in order to continue study agent&#xD;
             administration.&#xD;
&#xD;
          -  Clinical stage II-IVA (as defined by the American Joint Committee on Cancer, 8th&#xD;
             Edition) and amenable to surgical resection&#xD;
&#xD;
          -  New diagnosis of oral SCC, new second primary, or recurrent oral SCC following a&#xD;
             minimum remission of 6 months following previous definite surgery&#xD;
&#xD;
          -  History and physical examination by an otolaryngologist and medical oncologist within&#xD;
             14 calendar days of study registration&#xD;
&#xD;
          -  Study agent administration should start within 7 days of registration&#xD;
&#xD;
          -  Patient must receive administration of study agent for a minimum of 7 days&#xD;
&#xD;
          -  Zubrod Score/Eastern Cooperative Oncology Group (ECOG) Performance status &lt; 2.&#xD;
&#xD;
          -  Age ≥ 18 years.&#xD;
&#xD;
          -  Complete Blood Count (CBC)/differential obtained within 14 calendar days prior to&#xD;
             registration, with adequate bone marrow function defined as follows:&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) ≥ 1,500 cells/mm^3;&#xD;
&#xD;
               -  Platelets ≥ 100,000 cells/mm^3;&#xD;
&#xD;
               -  Hemoglobin ≥ 8.0 g/dl (Note: The use of transfusion or other intervention to&#xD;
                  achieve Hgb ≥ 8.0 g/dl is acceptable.);&#xD;
&#xD;
          -  Adequate renal and hepatic function within 14 calendar days prior to registration,&#xD;
             defined as follows:&#xD;
&#xD;
             o Serum creatinine &lt; 1.5 mg/dl or creatinine clearance (CCr) ≥ 50 ml/min within 14&#xD;
             calendar days prior to registration, determined by 24-hour collection or estimated by&#xD;
             Cockcroft-Gault formula: CCr male = [(140 - age) x (wt in kg)] [(Serum Cr mg/dl) x&#xD;
             (72)] CCr female = 0.85 x (CrCl male)&#xD;
&#xD;
          -  Total bilirubin &lt; 2 x the institutional upper limit of normal (ULN) within 14 calendar&#xD;
             days prior to registration&#xD;
&#xD;
          -  aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≤ 3 x the&#xD;
             institutional ULN within 14 calendar days prior to registration&#xD;
&#xD;
          -  Magnesium, calcium, glucose, potassium, and sodium within 14 calendar days prior to&#xD;
             registration, with the following required parameters:&#xD;
&#xD;
               -  Magnesium: &gt; 0.9 mg/dl or &lt; 3 mg/dl;&#xD;
&#xD;
               -  Calcium: &gt; 7 mg/dl or &lt; 12.5 mg/dl;&#xD;
&#xD;
               -  Glucose: &gt; 40 mg/dl or &lt; 250 mg/dl;&#xD;
&#xD;
               -  Potassium: &gt; 3 mmol/L or &lt; 6 mmol/L;&#xD;
&#xD;
               -  Sodium: &gt; 130 mmol/L or &lt; 155 mmol/L.&#xD;
&#xD;
          -  Female patients must meet one of the following:&#xD;
&#xD;
               -  Postmenopausal for at least one year before the screening visit, or&#xD;
&#xD;
               -  Surgically sterile (e.g., undergone a hysterectomy or bilateral oophorectomy), or&#xD;
&#xD;
               -  If subject is of childbearing potential (defined as not satisfying either of the&#xD;
                  above two criteria), agree to practice two acceptable methods of contraception&#xD;
                  (combination methods requires use of two of the following: diaphragm with&#xD;
                  spermicide, cervical cap with spermicide, contraceptive sponge, male or female&#xD;
                  condom, hormonal contraceptive) from the time of signing of the informed consent&#xD;
                  form through 90 days after the last dose of study agent, AND&#xD;
&#xD;
               -  Agree to practice true abstinence when this is in line with the preferred and&#xD;
                  usual lifestyle of the subject. (Periodic abstinence [e.g., calendar, ovulation,&#xD;
                  symptothermal, postovulation methods] and withdrawal are not acceptable&#xD;
                  contraception methods.)&#xD;
&#xD;
          -  Male patients, even if surgically sterilized (e.g., status post vasectomy), must agree&#xD;
             to one of the following:&#xD;
&#xD;
               -  Practice effective barrier contraception during the entire study period and&#xD;
                  through 60 calendar days after the last dose of study agent, OR&#xD;
&#xD;
               -  Must also adhere to the guidelines of any study-specific pregnancy prevention&#xD;
                  program, if applicable, OR&#xD;
&#xD;
               -  Agree to practice true abstinence when this is in line with the preferred and&#xD;
                  usual lifestyle of the subject. (Periodic abstinence [e.g., calendar, ovulation,&#xD;
                  symptothermal, post ovulation methods] and withdrawal are not acceptable methods&#xD;
                  of contraception.)&#xD;
&#xD;
          -  Patients must be deemed able to comply with the study plan.&#xD;
&#xD;
          -  Gastric tube study agent administration is permissible.&#xD;
&#xD;
          -  Patients must provide study-specific informed consent prior to study entry.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of active liver disease&#xD;
&#xD;
          -  Pregnant or lactating women are ineligible due to unforeseeable risks to embryo or&#xD;
             fetus.&#xD;
&#xD;
          -  Concurrent use of any medicinal botanical, natural, or other herbal compound/s that&#xD;
             the study PI believes could potentially impact the results/objectives of this study&#xD;
&#xD;
          -  Planned subtotal or debulking surgery, as determined by enrolling physician&#xD;
             determination, is not permissible.&#xD;
&#xD;
          -  Prior systemic chemotherapy for oral SCC; note that prior chemotherapy for a different&#xD;
             cancer is allowable.&#xD;
&#xD;
          -  Prior radiotherapy for oral SCC is permissible if disease free for 1 year since prior&#xD;
             oral cancer treatment and free of significant late radiation effects.&#xD;
&#xD;
          -  Severe active comorbidity such as uncontrolled cardiac disease, infection, severe&#xD;
             Chronic Obstructive Pulmonary Disease (COPD).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stuart Wong, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical College of Wisconsin</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Medical College of Wisconsin Cancer Center Clinical Trials Office</last_name>
    <phone>414-805-8900</phone>
    <email>cccto@mcw.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Froedtert Hospital and the Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cancer Center Clinical Trials Office</last_name>
      <phone>866-680-0505</phone>
      <phone_ext>8900</phone_ext>
      <email>cccto@mcw.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>March 1, 2018</study_first_submitted>
  <study_first_submitted_qc>March 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 9, 2018</study_first_posted>
  <last_update_submitted>September 15, 2021</last_update_submitted>
  <last_update_submitted_qc>September 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical College of Wisconsin</investigator_affiliation>
    <investigator_full_name>Stuart Wong</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Anti-tumor B</keyword>
  <keyword>ACAPHA</keyword>
  <keyword>Pharmacokinetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mouth Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

